Use of early chemotherapy for hormone-sensitive prostate cancer: Time for CHAARTED
- Author:
Jeanny B. ARAGON-CHING
1
Author Information
- Publication Type:Journal Article
- From: Asian Journal of Andrology 2016;18(3):444-445
- CountryChina
- Language:Chinese
- Abstract: CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy.
